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Abstract Glucosylgalactosylhydroxylysine (GGHYL), galacto- 
sylhydroxylysine (GHYL), pyridinoline (PYD) and deoxypyr- 
idinoline (DPD) were measured in the urine (6 h serial specimens 
over 96 and 24 h urine specimens for 4 days) collected from four 
adult Sprague Dawley rats and in the femoral and tibial bone as 
well as in the dorsal skin of the same rats. No significant daily 
variations were found in the urine excretion of GGHYL, GHYL, 
PYD and DPD but significant diurnal variations. The GGHYL! 
GHYL ratio in rat urine (0.46_+ 0.1) reflected neither the bone 
collagen ratio (1.9 to 2.4) nor the skin collagen ratio 
(1.22-+ 1.07), a finding that may reflect GGHYL conversion 
into GHYL. The content of both pyridinolines was very low in 
the skin and high in the bone collagen and the urinary PYD/DPD 
ratio (1.46-+ 0.15) reflected essentially the bone collagen ratio 
(0.8-3.0). These results suggest the usefulness of measuring 
GGHYL, GHYL, PYD and DPD in 24 h urine specimen and, 
based on the inter-animal variations, the necessity to consider 
each animal as its own control when bone turnover needs to be 
monitored. 
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1. Introduction 
Hydroxylysine glycosides (galactosylhydroxylysine or 
GHYL, and glucosylgalactosylhydroxylysine or GGHYL) 
and the residues of non-borohydride reducible cross-links (hy- 
droxylysylpyridinoline or PYD and lysylpyrydinoline or 
DPD) are components of collagen [1]. Since GHYL and 
GGHYL as well as PYD and DPD are the products of 
post-translational modifications in the pathway of collagen 
biosynthesis, they are not reutilized uring collagen turnover 
[1,2]. Thus, the urinary excretion of hydroxylysine glycosides 
and pyridinium cross-links residues specifically reflects col- 
lagen breakdown [3-6]. Recently, these two classes of metab- 
olites were proposed to represent markers of bone turnover in 
human bone diseases, with a specificity higher than that of 
hydroxyproline (HYP) [4,5,7-14], due to their selective pres- 
ence in type I bone collagen. In addition their metabolism is
less affected by non-specific nterferences and is not influenced 
by renal tubular eabsorption [15,16]. 
Interest has also grown in the use of these markers in ex- 
perimental animal models which may be relevant o human 
*Corresponding author (present address): Istituto Clinico Humanitas, 
Laboratorio di Analisi, Via Manzoni 56, 20089 Rozzano, Milan, Italy. 
Fax: (39) (2) 82242206. 
**Present address: Istituto Clinico Humanitas, Laboratorio di Analisi, 
Via Manzoni 56, 20089 Rozzano, Milan, Italy. 
bone remodelling diseases. In particular, PYD and DPD ex- 
cretion in the rat was reported to be increased by ovariectomy 
[17,18], experimental polyarthritis [18], dietary calcium restric- 
tion [19] and parathyroid hormone infusion [20]. Further- 
more, PYD and DPD levels in ovariectomized rats rose early 
with a significant peak 2 weeks after surgery [18]. 
The bone specificity of these markers in the rat has been 
also investigated by Robins and Duncan [21]. Some authors 
[17] have found that cortical bone contains higher concentra- 
tions of cross-links than trabecular bone, as observed in hu- 
mans. The bone collagen content of hydroxylysine glycosides 
in the rat has also been investigated by Moro et al. [22] who 
reported that the levels of glycosylation of type I collagen in 
cortical bone were not statistically different from those of 
trabecular bone. In particular, in these rat tissues, the 
GGHYL/GHYL ratio ranges from 1.6 to 2.3, a value which 
is considerably higher than that of 0.47 observed in man 
[23,24]. 
To date, at least two important questions, regarding the 
study on urinary excretion of these markers in the rat, remain 
open. Firstly, the biological variation of the urinary excretion 
of GGHYL, GHYL, PYD and DPD over time needs to be 
properly evaluated in order to better define which specimen 
(24 h vs spot urine) is most appropriate in order to measure 
these markers. Secondly, the glycosylation and cross-linkage 
of bone collagen eed to be better characterised, especially in 
the metaphysis, epiphysis and diaphysis of the distal femur 
and of the proximal tibia, the two segments of bone primarily 
involved in the experimentally induced osteopenia in the rat. 
Furthermore, rat skin collagen also needs to be better char- 
acterised since, due to its turnover, it might represent a source 
of type I collagen catabolites. 
The aim of this work was to study the biological variation 
in the urinary output of GGHYL, GHYL, PYD and DPD in 
the rat and to verify their specificity as bone marker. The 
urinary excretion of collagen catabolites was studied in 6 h 
serial specimens over a 96 h period and in 24 h urines from 
four adult Sprague Dawley rats for 4 days. In addition, the 
relative content of GGHYL, GHYL, PYD and DPD was 
measured in the rat femoral and tibial bone as well as in 
the dorsal skin. 
2. Materials and methods 
2.1. Materials 
All reagents used, purchased from BDH (UK), were of analytical 
grade. 
2.2. Urine and t&sue collection 
Mature male Sprague Dawley rats (n = 4) (Charles River, Milan, 
Italy), aged 90 days, weighing between 350 and 380 g, were main- 
tained at 22+ I°C and at 12 h light/dark cycle. The animals were 
0014-5793196l$12.00 © 1996 Federation of European Biochemical Societies. All rights reserved. 
PH S00 1 4 -5793(96)00505-4  
V. Graziofi et al./FEBS Letters 388 (1996) 134-138 135 
fed with a normal calcium diet (Mucedola, Milan, Italy) containing 
1% calcium, 0.85% phosphorus and 1260 IU/kg vitamin Da, and were 
allowed free access to food and water. After a week of acclimatisation, 
urine specimens were collected every 6 h for 4 consecutive days. All 
the urine specimens were collected in dark, sterile containers. Aliquots 
of urine were frozen at -80°C pending analysis. 
On the fifth day, the rats were killed with inhalation of diethyl 
ether. Left femurs and tibiae were collected and cartilage, tendons 
and adhering tissues were accurately removed. The bones were then 
submitted to densitometry (Hologic QDR 1000 Plus, USA) and phys- 
ical measurements in order to accurately dissect out segments of their 
respective diaphysis, metaphysis and epiphysis. The methaphysis dis- 
section limits were established in order to ensure inclusion of the 
growth plate; the bone segments were submitted to densitometry to
confirm their trabecular or cortical structure. A dorsal skin specimen 
(approx. 1 cm ~) was obtained from each animal and immediately 
frozen and kept at -135°C pending analysis. 
GGHYL (or GHYL) and pmol of PYD (or DPD)/nmol of collagen 
type I chains. The molarity of collagen type I chains was calculated on 
the basis of the hydroxyproline tissular content, expressed in nmol, 
assuming a ratio hydroxyproline/ctl (I) chain equal to 100. 
2.5. Bone mineral density (BMD) measurement 
BMD values were determined by using an X-ray bone densitometry 
(Hologlc QDR 1000 Plus, USA). The absorptiometer was adapted 
with a specially designed 1 mm collimator and a special software to 
measure BMD of small animals in vitro and in vivo. The CV of the 
technique was 1%. The BMD values were expressed in terms of g/cm 2. 
2.6. Statistical analysis 
Data are presented as mean + S.E.M. in tables and graphs. Signifi- 
cance of difference, between days and between rats, of the data ob- 
tained from the 24 h urine, was evaluated with analysis of multiple 
variance (MANOVA). 
2.3. Measurement of GGHYL, GHYL, total PYD and DPD and 
creatinine in urine 
GGHYL and GHYL were assayed according to a previously de- 
scribed method [25] using 500 ktl of the urine specimens diluted with 
9 ml of deionized water and 1 ml of 100 mM acetic acid. The detec- 
tion limit was 2 ktmol/1 for both the analytes; total inter-assay and 
intra-assay coefficients of variation (CV) were 5 and 7%, respectively. 
Total PYD and DPD were determined according to the method of 
Black et al. [26] using 250 I.tl of the urine specimens hydrolysed with 
250 /.tl of 12 N HC1 for 16 h at ll0°C. The detection limit was 20 
pmol/ml for both the analytes; total inter-assay and intra-assay CV 
were 10 and 13%, respectively. Urinary creatinine was measured by 
Jaffe' method (Boehringer Mannheim, Italy) using a Hitachi 911 ana- 
lyzer. In the 6 h urine specimens, the concentrations of GGHYL and 
GHYL were expressed as a function of the urinary creatinine (CR), in 
terms of nmol of GGHYL (or GHYL)/~tmol of CR; analogously, the 
PYD and the DPD concentrations were expressed as pmol of PYD 
(or DPD)/~tmol of CR. In the 24 h urine, the output of GGHYL, 
GHYL, PYD and DPD was expressed as nmol/24 h. 
2.4. Measurement of GGHYL, GHYL, total PYD and DPD, and HYP 
in tissues 
The segments of tibiae and femurs were delipidized with chloro- 
form:methanol 2:1 for 18 h at 4°C and decalcified with changes of 
0.5 M EDTA for 3 weeks. After washing with abundant distilled 
water, the segments were delipidized again, dried by vacuum centri- 
fugation (Savant 290, USA) and homogenised. The homogenate was 
hydrolysed in 6 N HC1 at ll0°C for 18 h. An aliquot of the homo- 
genate was also hydrolysed with 2.5 M sodium hydroxide at 110°C for 
18 h in order to determine hydroxylysine glycosides content as well 
(indeed, the strong acidity of the first procedure of hydrolysis with 6 N 
HC1 results in the hydrolysis of GGHYL and GHYL into hydroxy- 
lysine). For the measurement of GGHYL and GHYL, 60 ~tl of the 
basic hydrolysate were diluted with 30 ml of deionized water and 0.8 
ml of 5 M acetic acid; the sample was then submitted to the above- 
described procedure. To determine PYD and DPD, 500 ~tl of the acid 
hydrolysate were subjected to the above-described procedure. 
For the measurement of hydroxyproline, aliquots of the acid hydro- 
lysate were dried by vacuum centrifugation and derivatised with 4- 
dimethylaminoazobenzene-4'-sulfonyl chloride. The derivatisate was 
injected (20 Ixl) into a Spherisorb ODS2 25 cm x 0.46 cm I.D., 5 ~tm 
C18 reverse-phase column (Phase Separation, Deeside, Clwyd, UK), 
and the separation of the analyte was achieved in a gradient mode as 
previously described [27]. The detection limit was 22 ng/ml and total 
inter-assay and intra-assay CV were 6 and 9%, respectively. 
The tissue content of the analytes was expressed in terms of nmol of 
3. Results 
Table 1 summarises the results of analysis of multiple var- 
iance performed on data obtained by analysing 24 h urine 
samples from mature male rats: no significant variat ion be- 
tween days was noted in the excretion of hydroxylysine glyco- 
sides and pyridinolines. The same results were obtained when 
the data were expressed as a function of creatinine xcretion. 
Fig. la~ l  shows the fractional daily rhythms of the urinary 
excretion of GGHYL ,  GHYL ,  PYD and DPD,  respectively. 
The excretion of GGHYL  and GHYL  attained a peak value 
approximately at 19:00 h (Fig. la,b) whereas the urinary out- 
put of PYD and DPD attained a peak value at 07:00 h (Fig. 
lc,d). 
Fig. 2 summarises the results obtained by measuring the 
absolute content of glycosides (a), and pyridinolines (b) in 
bone collagen. Epiphyses appear to be the most glycosylated 
bone compartments,  in both femurs and tibiae, whereas the 
GGHYL/GHYL  ratio is substantial ly constant in the different 
segments, ranging from 1.89 to 2.38. The absolute content of 
3-hydroxypyridinium cross-links is comparable in all the bone 
segments, whereas the PYD/DPD ratio is greater in epiphyses 
(2.91-3.18), decreases in diaphyses (1.09-1.37) and is lowest in 
metaphyses (0.70-0.82), in both femurs and tibiae. 
The results of the analyses performed on dorsal skin speci- 
mens are shown in Fig. 3. It is interesting to underscore that, 
due to the great sensitivity of the method employed, it was 
also possible to measure the small quantit ies of PYD and 
DPD in the dorsal skin collagen of the rat. 
The differences between human and rat in terms of relative 
content of  GGHYL ,  GHYL,  PYD and DPD in urine, bone 
collagen and skin collagen are summarised in Table 2. The 
urinary GGHYL/GHYL  ratio is lower in the rat than in the 
human and does not reflect the relative content of the glyco- 
sides either in bone or in skin collagen. In contrast he urinary 
PYD/DPD ratios in the rat, although lower than in humans, 
reflects the relative content of pyridinolines in bone. 
Table 1 
Multifactor analysis of variance between days performed on the data obtained by analysing 24 h urine of mature male rats 
Parameters 1st day 2nd day 3rd day 4th day P values 
GGHYL (nmol/24 h) 391.00 + 90.73 419.25 + 56.27 407.96 + 57.22 406.03 _+ 23.61 NS 
GHYL (nmol/24 h) 836.75 + 197.20 885.25 + 41.30 913.25 + 66.10 907.75 + 54.30 NS 
PYD (nmol/24 h) 19.59 + 1.88 25.81 _+ 1.01 23.62 _+ 2.26 25.37 + 1.51 NS 
DPD (nmol/24 h) 13.27 + 0.98 18.78 + 1.20 15.61 + 0.87 17.03 _+ 2.00 NS 
Values (means + S.E.M.) are expressed as absolute daily output. 
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Fig. 1. Fractional daily urinary excretion of glucosylgalactosylhydroxylysine (GGHYL) (a), galactosylhydroxylysine (GHYL) (b), pyridinoline 
(PYD) (c) and deoxypyridinoline (DPD) (d) in mature male rats. The urine was collected, starting from 17:00 h, every 6 h for 4 consecutive 
days. The urinary output of GGHYL, GHYL, PYD and DPD varies ignificantly within day (p < 0.001 for GGHYL, PYD and DPD, p < 0.01 
for GHYL). 
4. D iscuss ion 
The rat is the animal most commonly used to evaluate the 
effects of bone turnover perturbations induced by ovariec- 
tomy, parathyroidectomy, dietary calcium restrictions and im- 
mobilisation as well as the effects of therapeutic nterventions 
related to these pathologies [17-19]. Although it is well known 
that histomorphometric and densitometric techniques do not 
allow continuous monitoring of the bone turnover in small 
laboratory animals [20-22], this evaluation may be possible 
by measuring the urinary output of some specific bone col- 
lagen catabolites, such as urinary pyridinolines and the 
hydroxylysine glycosides. In order to identify the most appro- 
priate specimen i  which to measure the urinary concentration 
of the markers studied, the urinary output of GGHYL, 
GHYL, PYD and DPD was monitored over 4 consecutive 
days in four adult male rats (90 days old). At this age rats 
are characterised by a very low growth rate, and the length of 
the experimental period (4 consecutive days) permitted further 
minimisation of the effect of growth on bone turnover and, 
therefore, on the markers' excretion. Furthermore, male rats 
were chosen in order to exclude any possible interference with 
bone turnover caused by the ovulatory cycle. 
Our results indicate that the 24 h urine is the best specimen 
to measure the excretion of the considered markers. In fact, 
substantial variation of the urinary excretion of pyridinolines 
and hydroxylysine glycosides between different days was not 
observed, whereas a significant diurnal variation was evident. 
This diurnal variation represents a potentially interesting re- 
suit, for at least two reasons. Firstly, the fluctuations observed 
seem to be periodical, in agreement with the diurnal periodi- 
city in the metabolic activity of bone demonstrated by Mtihl- 
bauer and Fleisch [28]; this finding also confirms the high 
sensitivity of these markers in detecting small variations of 
bone turnover rate like those that physiologically occur within 
a day. Furthermore, the 12 h phase difference between the 
peaks of glycosides and pyridinolines suggests that hydroxy- 
lysine glycosides are more likely markers of both bone resorp- 
tion and bone formation rather than indicating a difference in 
the metabolic pathways of the two classes of catabolites. In 
this regard, while the source of pyridinolines i undoubtedly 
the mature collagen, the source of GGHYL and GHYL could 
be also the intracellular breakdown of new synthetized pro- 
collagen demonstrated by Bienkowski et al. [29] in cultured 
fibroblasts. 
In order to investigate the bone specificity of the markers 
under study, we compared their urinary concentration with 
their absolute and relative tissue content. Therefore, the 
four adult male rats were killed at the end of the experimental 
period, in order to analyse the tissues that, due to their turn- 
over, could contribute to the urinary excretion of the collagen 
catabolites. Even if both pyridinolines are detectable in the 
skin, our results confirm that PYD and DPD are present, 
almost exclusively, in the bone tissue. Particularly, in contrast 
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Fig. 2. Relative distribution of hydroxylysine glycosides (GGI-IYL 
and GHYL) (a) and pyridinolines (PYD and DPD) (b) in epipbysis 
(EPI), metapbysis (META) and diaphysis (DIA) of femur and tibia 
of the mature male rats. 
to epiphyses and diaphyses, methaphyses are richer in DPD 
than in PYD (with a PYD/DPD ratio ranging from 0.70 to 
0.95) suggesting that hydroxylysine is relatively less available 
in this compartment for the formation of  PYD, which embod- 
ies three hydroxylysines. As a consequence, the pathways of 
cross-linking in the hydroxyallysine route deviate preferen- 
tially toward the formation of DPD, which embodies two 
hydroxylysines and one lysine. The scarcity of hydroxylysine 
in methaphyses i  likely due to a low lysyl hydroxylase activ- 
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Fig. 3. Absolute and relative content of PYD, DPD, GGHYL and 
GHYL in dorsal skin. Values are expressed as mean + S.E.M. 
ity, which is known to vary greatly among different tissues 
[30]. The glycosylation of bone and skin collagen is substan- 
tially comparable in terms of both absolute and relative con- 
tent of GGHYL  and GHYL,  although if epiphyses appear to 
be more glycosylated than methaphyses and diaphyses. In rat 
bone collagen, we found that the GGHYL/GHYL  ratio 
ranges from 1.9 to 2.4, confirming previous report [22]; this 
value is considerably higher than that observed in man [24]. 
We compared the relative urinary concentration of the mar- 
kers with their relative tissue content. In rat, as well as in 
human, the urinary PYD/DPD ratio reflects essentially the 
bone collagen ratio, confirming that the bone is the main 
source of pyridinolines, whilst the urinary GGHYL/GHYL  
ratio can be related neither to the bone collagen ratio nor 
to the skin collagen ratio, indicating that urinary GHYL  
does not appear so bone-specific as in human. However, the 
rat urinary GGHYL/GHYL  ratio could be likely explained by 
the conversion of GGHYL  into GHYL:  in these regards, the 
presence of a specific ct-glucosidase in rat kidney has been 
reported [31] and, therefore, we cannot exclude the existence 
of such a metabolic step in one or more compartments of the 
rat. These considerations suggest o use total urinary excretion 
of hydroxylysine glycosides (GGHYL+GHYL) ,  a parameter 
that is not affected by the likely transformation of GGHYL  
into GHYL.  
Table 2 
Relative content of pyridinolines and hydroxylysine glycosides in urine, bone and skin collagen from human and rat 
Specimen Human Rat 
PYD/DPD GGHYL/GHYL PYD/DPD GGHYL/GHYL 
Urine 5.17-+ 1.1 ~ 1.33+0.17 (3) 
3.0 -+ 0.4 (2) 1.5 _+ 0.28 (7) 
1.75 _+ 0.54 (33) 
Bone collagen 0.15 (1) 
0.47 (7) 
4.0 (1) 
Skin collagen - 1.61 (3) 
1.46+0.15 a 0.46+0.1 ~
femoral EPI 3.182+0.780 femoral EPI 2.015+0.164 
femoral META 0.821 +0.126 femoral META 2.226_+0.279 
femoral DIA 1.370 _+ 0.312 femoral DIA 2.361 _+ 0.167 
tibial EPI 2.910 _+ 2.371 tibial EPI 1.892 _+ 0.237 
tibial META 0.701 _+ 0.040 tibial META 2.377 _+ 0.360 
tibial DIA 1.079 _+ 0.283 tibial DIA 1.220 _+ 0.066 
2.508 _+ 0.44 1.220 _+ 0.07 
EPI, epiphysis; DIA, diaphysis; META, metaphysis. 
aOur observations. 
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In conclusion, urinary GGHYL,  GHYL, PYD and DPD 
seem to be very specific and sensitive markers of bone turn- 
over rate in the rat and to represent a powerful tool for a 
continuous, rapid and economical monitor of bone remodel- 
ling in this animal. Our results suggest he usefulness of meas- 
uring all these markers in the 24 h urine specimen and of 
including the hydroxylysine glycosides in order to avoid bias 
due to unknown catabolic pathways in their metabolism. In 
addition, we suggest o express the results as mol excreted per 
day since the urinary excretion of glycosides and pyridino- 
lines, and consequently their correlation with creatinine, has 
not yet been fully elucidated. As a consequence, the bias due 
to possible variations within and between methods in the 
measurement of urinary creatinine is avoided. Finally, to 
avoid a possible significant variation between subjects, it is 
likely necessary to consider each rat as its own control and 
to express the results as MKt/MKo (were MKt = marker out- 
put at time t; MKo = basal marker output) in order to nor- 
malized the variations of the bone turnover ate respect o an 
initial point. 
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